Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 20/20 | 1.00 |
| ▸ | HTR1A | P08908 | 2/20 | 0.77 |
| ▸ | DRD2 | P14416 | 2/20 | 0.77 |
| ▸ | HTR1D | P28221 | 2/20 | 0.77 |
| ▸ | HTR1B | P28222 | 2/20 | 0.77 |
| ▸ | HTR1F | P30939 | 2/20 | 0.77 |
| ▸ | HTR7 | P34969 | 2/20 | 0.77 |
| ▸ | DRD3 | P35462 | 2/20 | 0.77 |
| ▸ | HTR1E | P28566 | 1/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5499070 | 0.87 | HTR6 (1.00) | HTR6HTR1ADRD2HTR1DHTR1B | |
| SCHEMBL29720339 | 0.87 | HTR6 (1.00) | HTR6HTR1ADRD2HTR1DHTR1B | |
| Oxalic Acid SCHEMBL5762121 | 0.84 | HTR6 (0.92) | HTR6HTR1ADRD2HTR1DHTR1B | |
| Oxalic Acid SCHEMBL7430614 | 0.83 | HTR6 (0.71) | HTR6HTR1ADRD2HTR1DHTR1B | |
| SCHEMBL5504710 | 0.83 | HTR6 (1.00) | HTR6HTR1ADRD2HTR1DHTR1B | |
| SCHEMBL5499078 | 0.81 | HTR6 (1.00) | HTR6HTR1ADRD2HTR1DHTR1B | |
| SCHEMBL3322247 | 0.80 | HTR6 (1.00) | HTR6HTR1ADRD2HTR1DHTR1B | |
| SCHEMBL5030681 | 0.80 | HTR6 (0.66) | HTR6HTR1ADRD2HTR1DHTR1B | |
| SCHEMBL13940270 | 0.79 | PPARG (0.80) | HTR6HTR1ADRD2HTR1DHTR1B | |
| SCHEMBL5498952 | 0.78 | HTR6 (1.00) | HTR6HTR1ADRD2HTR1DHTR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1438045-B1 | USE OF INDOLE AND INDOLINE DERIVATIVES IN THE TREATMENT OF OBESITY OR FOR THE REDUCTION OF FOOD INTAKE | BIOVITRUM AB (SE) | 2007-02-14 | — | — | EP | claimed |
| US-20030139424-A1 | Use | BIOVITRUM AB (SE) | 2003-07-24 | — | — | US | claimed |
| US-6187805-B1 | TREATING CONDITION FOR WHICH SELECTIVE AGONISM OR ANTAGONISM OF 5-HT-6 RECEPTORS IS INDICATED BY ADMINISTERING COMPOUNDS SUCH AS N,N-DIMETHYL 2-(1-(BENZENESULPHONYL)-5-METHOXY-1H-INDOL-3-YL)ETHYLAMINE | MERCK SHARP & DOHME LTD. (GB) | 2001-02-13 | — | — | US | claimed |
| EP-1438045-B1 | USE OF INDOLE AND INDOLINE DERIVATIVES IN THE TREATMENT OF OBESITY OR FOR THE REDUCTION OF FOOD INTAKE | BIOVITRUM AB (SE) | 2007-02-14 | — | — | EP | disclosed |
| EP-1438045-A1 | USE OF INDOLE AND INDOLINE DERIVATIVES IN THE TREATMENT OF OBESITY OR FOR THE REDUCTION OF FOOD INTAKE | BIOVITRUM AB (SE) | 2004-07-21 | — | — | EP | disclosed |
| US-20030139424-A1 | Use | BIOVITRUM AB (SE) | 2003-07-24 | — | — | US | disclosed |
| WO-2003035061-A1 | USE OF INDOLE AND INDOLINE DERIVATIVES IN THE TREATMENT OF OBESITY OR FOR THE REDUCTION OF FOOD INTAKE | BIOVITRUM AB (SE) | 2003-05-01 | — | — | WO | disclosed |
| US-6187805-B1 | TREATING CONDITION FOR WHICH SELECTIVE AGONISM OR ANTAGONISM OF 5-HT-6 RECEPTORS IS INDICATED BY ADMINISTERING COMPOUNDS SUCH AS N,N-DIMETHYL 2-(1-(BENZENESULPHONYL)-5-METHOXY-1H-INDOL-3-YL)ETHYLAMINE | MERCK SHARP & DOHME LTD. (GB) | 2001-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030139424-A1 | Use | TPH1, IDO1, TPH2 | HTR6 25/4885HTR1A 32/4885DRD2 617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.